Gut Health Trends

Metabolic syndrome (MetS) included central obesity, high blood sugar, abnormal blood lipid, high blood pressure and uric acid — interrelated metabolic risk factors became major global public health challenge in recent years. A bidirectional Mendelian randomization study published in 2025 used large-scale genetic data to explore the causal relationship between gut microbiota and metabolic syndrome. The results confirmed that specific gut microbiota directly influenced the risk of metabolic syndrome by affecting host metabolism. It regulated gut microbiota not only an auxiliary method, but also one of the fundamental strategies improving metabolic syndrome.

GKM3™ Lactobacillus plantarum was proven through multiple patents and clinical studies for various effects against metabolic syndrome:

- Lower blood lipid: reduce triglyceride & cholesterol & cardiovascular burden

- Lower uric acid: improve uric acid levels, helpful for social life

- Fight inflammation: improve liver inflammation & liver function indices

- Lower blood sugar: improve fasting blood sugar, stabilize metabolism

- Reduce liver enlargement: lower total liver lipids, improve fatty liver

Relevant GKM3™ patents include:

- Taiwan Patent 1636133: eliminate body fat & liver enlargement, fight inflammation

- Taiwan Patent 1636134: lower blood lipid, liver function indice, uric acid

- Taiwan Patent 1634207: lower uric acid & blood sugar, improve allergies

NutriBeyond 73⁺ patented GKM3™ strain providing scientifically probiotic solution for people with three highs, fatty liver and metabolic syndrome.